F
Fennec Pharmaceuticals
Biotechnology company developing sodium thiosulfate
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX) is a specialty pharmaceutical company focused on developing a unique formulation of sodium thiosulfate (STS) to prevent platinum-induced ototoxicity in pediatric patients. Ototoxicity refers to ear poisoning, which can result in hearing loss, caused by platinum-based chemotherapy drugs. The company operates in the healthcare and pharmaceutical market, primarily targeting pediatric oncology patients who are undergoing chemotherapy treatments.
Fennec's business model revolves around the research, development, and commercialization of its core product, STS. The company has completed two pediatric phase 3 clinical trials and plans to file for regulatory approval. Revenue generation will primarily come from the sale of STS upon approval and subsequent commercialization.
Fennec serves a niche market of pediatric patients and healthcare providers specializing in oncology. The company aims to address a significant unmet medical need, providing a solution that can improve the quality of life for young cancer patients by preventing hearing loss associated with chemotherapy.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1996
- Headquarters
- Durham, United States
- Listing
- IPO 2004
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
HBM Healthcare Investments
Series B and later1 investor entered at this stage
- PEPetrichor
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fennec Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fennec Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.